Elevated liver enzymes: what ALT, AST, and GGT actually tell you.

What liver enzymes actually are

When your blood test shows ALT, AST, and GGT, you are not measuring liver "function" per se — you are measuring liver cell damage. These enzymes are normally contained inside liver cells (hepatocytes). When hepatocytes are damaged, inflamed, or dying, they release their contents into the bloodstream. Higher levels mean more damage[1].

Think of it this way: ALT, AST, and GGT are like a smoke detector for your liver. They do not tell you what is burning — only that something is. The pattern of elevation, the ratios between them, and the clinical context narrow down the cause.

ALT (alanine aminotransferase): the liver-specific marker

ALT is the most liver-specific of the three. It is found predominantly in liver cells and at low concentrations in other tissues. When ALT is elevated, the liver is the presumptive source[1].

Standard reference ranges for ALT are typically listed as up to 35-40 U/L for men and 25-35 U/L for women. However, these ranges were derived from populations that include people with undiagnosed fatty liver, subclinical hepatitis, and metabolic syndrome. Updated recommendations from the American College of Gastroenterology suggest tighter upper limits: 33 U/L for men and 25 U/L for women[2].

This means a man with an ALT of 38 U/L — which most labs call "normal" — may actually have mildly elevated liver enzymes. This is particularly relevant for NAFLD screening, where even mildly elevated ALT indicates excess liver fat in the right clinical context.

AST (aspartate aminotransferase): the less specific marker

AST is found in the liver but also in significant concentrations in the heart, skeletal muscle, kidneys, brain, and red blood cells. An elevated AST can come from[1]:

• Liver disease (any cause)
• Intense exercise — particularly resistance training or endurance exercise. AST can remain elevated for 24-72 hours after vigorous exercise.
• Muscle damage (rhabdomyolysis, crush injury)
• Cardiac injury (myocardial infarction — AST was the original cardiac enzyme test before troponin)
• Hemolysis (red blood cell destruction)

If AST is elevated but ALT is normal, the source is probably not the liver. Check creatine kinase (CK) to assess muscle damage, and consider recent exercise history.

GGT (gamma-glutamyl transferase): the sensitive sentinel

GGT is a sensitive but non-specific marker. It is elevated in liver disease, bile duct obstruction, pancreatic disease, alcohol use, metabolic syndrome, and as a response to many medications. It is also induced by enzyme-inducing drugs (certain anticonvulsants, barbiturates) and even moderate alcohol intake[3].

GGT's clinical value is twofold:

• Distinguishing liver from bone/muscle sources: If alkaline phosphatase (ALP) is elevated and GGT is also elevated, the source is likely hepatobiliary. If ALP is elevated but GGT is normal, the source is likely bone.
• Alcohol use marker: GGT is very sensitive to alcohol. Even moderate regular drinking (2-3 drinks/day) can elevate GGT. It is commonly used to assess alcohol-related liver effects and to monitor abstinence.

Importantly, GGT is an independent predictor of cardiovascular mortality, type 2 diabetes, and all-cause mortality — even at levels within the "normal" range[3]. It appears to reflect oxidative stress and subclinical inflammation beyond its role as a liver enzyme.

The De Ritis ratio: AST/ALT

The ratio of AST to ALT (the De Ritis ratio) was first described in 1957 and remains one of the most useful diagnostic tools in hepatology[1]:

In NAFLD, as the disease progresses from simple steatosis to steatohepatitis to fibrosis, the De Ritis ratio tends to increase — ALT falls relative to AST because fibrotic liver tissue releases proportionally more AST. A De Ritis ratio that was below 1.0 and is now trending above 1.0 can signal disease progression.

NAFLD/MASLD: the elephant in the liver

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is now the most common liver disease globally, affecting approximately 25-30% of adults in developed countries and up to 50-70% of people with type 2 diabetes or obesity[4].

NAFLD/MASLD exists on a spectrum:

1. Simple steatosis: Excess fat in the liver without significant inflammation. ALT may be normal or mildly elevated. Generally benign with low progression risk.
2. NASH/MASH (steatohepatitis): Fat plus inflammation and hepatocyte ballooning. ALT typically elevated, often 1-3x upper limit. This is the stage where fibrosis begins.
3. Fibrosis: Progressive scarring. Liver enzymes may paradoxically normalize as functional tissue is replaced. Non-invasive fibrosis scores (FIB-4) help assess this.
4. Cirrhosis: Irreversible scarring. Liver enzymes often normalize. Albumin and platelets drop. Bilirubin rises.

The FIB-4 score: assessing fibrosis without biopsy

FIB-4 is a simple, validated formula that estimates the degree of liver fibrosis using four readily available values: age, AST, ALT, and platelet count[5].

FIB-4 = (Age x AST) / (Platelet count x sqrt(ALT))

• FIB-4 < 1.3: Low risk of advanced fibrosis (negative predictive value >90%). Reassuring.
• FIB-4 1.3-2.67: Indeterminate. May need further testing (elastography/FibroScan).
• FIB-4 > 2.67: High probability of advanced fibrosis. Refer to hepatology.

Lipa calculates your FIB-4 automatically from your blood test. This is one of the most clinically valuable calculations that can be derived from routine blood work.

Causes of elevated liver enzymes beyond NAFLD

"Normal" ALT is not always healthy

A critical nuance: a substantial portion of people with NAFLD have ALT levels within the standard reference range. Studies using liver biopsy or imaging as the gold standard have shown that up to 25% of people with significant hepatic steatosis have normal ALT[4].

This is why the tighter thresholds (33 U/L for men, 25 U/L for women) are important, and why ALT should always be interpreted alongside metabolic context. A man with an ALT of 35, BMI of 31, fasting glucose of 108, and triglycerides of 220 almost certainly has NAFLD — even though his ALT is technically "normal."

Lifestyle interventions: what the evidence shows

Weight loss

Weight loss is the single most effective intervention for NAFLD/MASLD[6]:

• 3-5% weight loss: Reduces hepatic steatosis (liver fat)
• 5-7% weight loss: Resolves steatohepatitis (NASH) in most patients
• 7-10% weight loss: Begins to improve fibrosis
• >10% weight loss: Can reverse established fibrosis in many patients

Exercise

Exercise reduces liver fat independently of weight loss. Both aerobic exercise and resistance training have been shown to reduce hepatic steatosis in RCTs. The benefit appears even without significant weight change — exercise improves insulin sensitivity and reduces de novo lipogenesis (the liver's production of new fat)[7].

Diet

Mediterranean diet patterns consistently show the strongest evidence for NAFLD improvement[7]:

• Reduce: Sugar-sweetened beverages (fructose is directly lipogenic in the liver), refined carbohydrates, processed foods
• Increase: Olive oil, fatty fish (omega-3s), vegetables, nuts, whole grains
• Coffee: 2-3 cups of coffee per day is consistently associated with lower ALT, lower fibrosis risk, and reduced hepatocellular carcinoma risk in NAFLD[8]

Alcohol

For alcohol-related liver enzyme elevation, abstinence is the primary intervention. GGT typically normalizes within 2-6 weeks of abstinence, and ALT/AST within 4-8 weeks[1]. For NAFLD with moderate alcohol use, reducing intake is beneficial because alcohol and metabolic liver fat are synergistic — they compound each other's damage.

Medications and liver enzymes

Several common medications can elevate liver enzymes[9]:

• Statins: Mild ALT elevation (1-3x) occurs in 1-3% of patients. Current guidelines do not recommend routine liver enzyme monitoring on statins, and mild elevations are not a reason to stop therapy. Statins are actually beneficial in NAFLD.
• Acetaminophen (paracetamol): The leading cause of acute liver failure. Doses above 4g/day (or lower with alcohol use) can cause severe hepatotoxicity.
• NSAIDs: Occasional mild enzyme elevations. Diclofenac is the most hepatotoxic NSAID.
• Antibiotics: Amoxicillin-clavulanate is the most common cause of drug-induced liver injury in many countries.
• Supplements: Green tea extract (high-dose), kava, certain weight-loss supplements can cause significant liver injury.

When to worry: the red flags

Most mildly elevated liver enzymes (1-3x upper limit) do not represent an emergency. However, certain patterns require prompt medical evaluation[1]:

• ALT or AST > 10x upper limit: Acute hepatitis — viral, drug-induced, or ischemic. Needs urgent evaluation.
• Rising bilirubin with elevated enzymes: Suggests either biliary obstruction or significant hepatocellular damage.
• Falling albumin or platelets with chronic enzyme elevation: May indicate progression to fibrosis or cirrhosis.
• Jaundice (yellow skin/eyes): Always urgent regardless of enzyme levels.
• INR prolongation (elevated PT): Indicates liver synthetic function is compromised.

Monitoring timeline

• Mildly elevated ALT (1-2x) with clear metabolic cause: Recheck in 3-6 months after lifestyle intervention. If improving, continue monitoring every 6 months.
• Moderately elevated (2-5x): Investigate cause (viral serology, autoimmune markers, iron studies, celiac screen). Recheck in 4-8 weeks.
• Highly elevated (>5x): Urgent evaluation. Consider drug-induced injury, acute viral hepatitis, or other acute causes.
• After starting a new medication: Recheck in 4-8 weeks if the drug is known to affect liver enzymes.